Dopegyt tabs 250mg #50

Dopegyt instruction for use

Reed more and buy Dopegyt here

Composition

In 1 tablet contains 250 mg of active substance methyldopa (in the form of methyldopa sesquihydrate).
Additional components are: ethylcellulose, talc, magnesium stearate, starch, sodium carboxymethyl starch, stearic acid.

Form of issue

Dopegyt is available in tablet form.

pharmachologic effect

Central alpha-2-adrenostimulator.

Pharmacodynamics and pharmacokinetics

The active ingredient is methyldopa. The drug reduces the heart rate and IOC, providing antihypertensive effect, lower OPSS. In the central nervous system, a metabolite of the drug, alpha-methylnorepinephrine, is formed, which reduces the tone of the vessels and inhibits sympathetic impulses. The medication moderately suppresses the activity of renin, causes orthostatic hypotension, reduces OPSS, reduces the tissue concentration of epinephrine, dopamine, and serotonin. Dopegyt does not significantly affect the renal blood flow and IOC, but increases the volume of plasma. Long-term therapy leads to a regression of the size of the hypertrophied left ventricle, an increase in collagen is observed in the myocardium.
Taking the first dose leads to short-term hypertension. In the period of intensive physical exertion, the intensity of the hypotensive effect decreases. The drug promotes the retention of water and sodium ions in the body, slows down the sinus rhythm, increases the activity of baroreceptors, which leads to the possible development of refractoriness with prolonged therapy (1-1.5 months). The medication is characterized by a "cancellation" syndrome. Dopegyt can induce sedation, the severity of which decreases after 2-3 weeks after the start of therapy.
The maximum drop in blood pressure is recorded after 4-6 hours, the effect lasts 1-2 days. The severity of the hypotensive effect increases gradually. With intravenous infusion of the drug, the drop in blood pressure is recorded after 2-3 hours, the peak is noted after 3-5 hours, the effect lasts 6-10 hours. The drug enhances kidney blood flow.

Indications for use

Instructions for use Dopegyt recommends that it be prescribed for arterial hypertension of mild to moderate severity.

Contraindications

Dopegyt is not used for acute hepatitis, methyldopa intolerance, acute myocardial infarction, systemic connective tissue diseases, severe liver and renal system pathology, pheochromocytoma, depression, cerebral arteriosclerosis, Parkinsonism, hemolytic anemia, simultaneous therapy with levodopa and MAO inhibitors. expressed coronary atherosclerosis.
With diencephalic syndrome, acute left ventricular failure, with hepatitis in a history of medication prescribed with caution.

Side effects

Nervous system: spontaneous choreoathetoid movements of limbs, parkinsonism, inhibition, dizziness, staggering when walking, headaches, paralysis of the facial nerve, lethargy and drowsiness.
Cardiovascular system: pericarditis, hyperemia of the upper body skin, peripheral edema, bradycardia, orthostatic hypotension, myocarditis, aggravation of the course of heart failure.
The digestive tract: icterus, colitis, hepatotoxicity, increased liver enzymes, vomiting, glossalgia, pancreatitis, diarrhea, dry mouth, nausea.
Hematopoiesis: thrombocytopenia, agranulocytosis, hemolytic anemia, and leukopenia.
Musculoskeletal system: development of arthralgia, myalgia.
Endocrine system: decreased libido, amenorrhea, decreased potency.
Allergic reactions are possible in the form of exanthema, Lyell syndrome, febrile syndrome, rash. Long-term therapy can cause a positive Coombs test. On the background of treatment, inflammation of the salivary glands is possible, nasal congestion.

Dopegyt tablets, instructions for use (Method and dosage)

In the first 2 days, 250 mg are prescribed in the evening, then once a day the dosage is increased by 250 mg every 2 days until the desired and optimal hypotensive effect is reached (the standard scheme is 1 gram of methyldopa for 2-3 sessions).
It is possible to increase the evening dose of the drug to reduce the severity of sedation. A day prescribed no more than 2 grams of medication (with combined therapy with other antihypertensive drugs - methyldopa prescribed not more than 500 mg / day). After reaching and stabilizing the required antihypertensive effect, the amount of medication is gradually reduced to the minimum effective dosage.
Warn the syndrome "cancellation" can be a gradual decrease in the amount of methyldopa.
According to the instructions for the use of patients with severe pathology of the renal system, it is recommended to reduce the single dosage.

Overdose

It is manifested by intestinal atony, inhibition, drop in blood pressure, vomiting, flatulence, bradycardia, limb tremor, diarrhea, drowsiness.
It requires urgent conducting forced diuresis, gastric lavage, the appointment of adrenostimulators.

special instructions

Treatment with methyldopa requires regular monitoring of the functional parameters of the liver system, the state of peripheral blood.
Dopegyt is able to mask hyperthermia in infectious diseases.
The medication affects the result of the determination of serum creatinine, uric acid, etc.
When storing the urine of patients taking Dopegyt, acquires a darker shade.
The drug is canceled when a positive Coombs reaction is detected, with the diagnosis of hemolytic anemia.
Peripheral blood parameters can independently normalize during treatment, in some cases, the appointment of glucocorticosteroids.
It is not allowed to drink alcohol-containing beverages.
Dopegyt is able to have a negative impact on the management of motor vehicles, concentration of attention.

Terms of sale

The prescription is not required to buy Dopegyt online.

Storage conditions

In a place inaccessible to children at a temperature of 15-25 degrees Celsius.
Shelf life not more than five years.

Interaction

Increased severity of side effects is observed with simultaneous therapy with MAO inhibitors (psychomotor agitation, severe arterial hypertension or hypotension).
In the treatment of tricyclic antidepressants, headaches, agitation, tachycardia, a decrease in the severity of the hypotensive effect are noted.
The combination with levodopa causes an increase in the antiparkinsonian effect, which is explained by the inhibition of the decarboxylation process of levodopa at the periphery under the influence of methyldopa and an increase in the level of levodopa in the central nervous system.
But with the predominance of inhibition of decarboxylation in the central nervous system, there is a decrease in the severity of the antiparkinsonian effect of levodopa.
Orthostatic hypotension is observed with simultaneous therapy with medicines containing carbidopa and levodopa (recommended within 2 hours after taking the drug in a horizontal position).
The risk of developing sinus node weakness is increased by the joint treatment of elderly patients with digoxin; Dementia develops when taking haloperidol.
Joint therapy with beta-blockers causes orthostatic hypotension, possibly raising the level of blood pressure.
Strengthening of the hypotensive effect is observed in the appointment of nifedipine, diuretic medicines and hydralazine.
Simultaneous therapy with indomethacin, adrenostimulants, drugs of the NSAID group leads to a decrease in the severity of the hypotensive effect.
Tranquilizers (anxiolytics) are able to enhance the hypotensive effect. With acidification of urine against the background of methyldopa, its effect is reduced, and when it becomes alkaline, it increases. In patients who receive methyldopa during general anesthesia, collapoid conditions may develop, so the drug is canceled 7-10 days before the proposed surgery.
Dopegyt is prescribed with caution to patients who receive thiopental sodium, fluorothane and other medicines for general anesthesia. Ethyl ether is contraindicated.
The drug is incompatible with diacarb, procainamide, quinidine, antipsychotics.
Dopegyt is able to enhance the hepatotoxicity of oral contraceptives; increase the toxicity of lithium salts.

Dopegyt during pregnancy

According to the instructions of the pill during pregnancy and breastfeeding is not recommended to use, as there is a hypothesis about the possible harm to the child, although there is no clinical evidence for this, and the reviews on Dopegitis during pregnancy also do not have information about the harmful effects of the drug.
The active substance penetrates the placental barrier. Dopegyt during breastfeeding is able to penetrate the mother's milk.
If the medicine has been prescribed, then it should be taken under strict medical supervision.
Thus, a drug can be prescribed only if the potential benefit to the mother is greater than the possible harm to the child.

Reviews about Dopegyt

Reviews characterize the drug as an inexpensive, affordable means to reduce blood pressure.